Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8728856 | 0.98 | TP53 (0.51) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL1070543 | 0.98 | TP53 (0.56) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL21388518 | 0.95 | PLA2G2A (0.56) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL17835021 | 0.93 | PLA2G2A (0.59) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL12550198 | 0.93 | PLA2G2A (0.59) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL1071885 | 0.93 | TP53 (0.50) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL14331832 | 0.88 | PLA2G2A (0.48) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL12749081 | 0.88 | TP53 (0.63) | TP53ALOX15PLA2G2ATSHRALDH1A1 | |
| SCHEMBL8956013 | 0.86 | TP53 (0.54) | TP53ALOX15PLA2G2ATSHRNR5A1 | |
| SCHEMBL8778517 | 0.86 | PLA2G2A (0.49) | TP53ALOX15PLA2G2ATSHRNR5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0647610-B1 | A process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL (JP) | 1998-08-19 | — | — | EP | claimed |
| US-5416256-A | Process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1995-05-16 | — | — | US | claimed |
| EP-0647610-A1 | A process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1995-04-12 | — | — | EP | claimed |
| JP-7109246-A | — | — | None | — | — | JP | disclosed |
| EP-1495034-A2 | MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030236213-A1 | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses | ESPERION THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| WO-2003087040-A2 | MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0647610-B1 | A process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5416256-A | Process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| US-5416256-A | Process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| JP-H07109246-A | PRODUCTION OF 5-HYDROXYISOPHTHALIC ACID | SUMIKIN CHEM CO LTD | 1995-04-25 | — | — | JP | disclosed |
| EP-0647610-A1 | A process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0647610-A1 | A process for manufacturing 5-hydroxyisophthalic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1995-04-12 | — | — | EP | disclosed |
| US-4952721-A | AIR OXIDATION WITH HEAVY METAL CATALYSTS | AMOCO CORPORATION (US) | 1990-08-28 | — | — | US | disclosed |
| US-4692546-A | OXIDATION OF KETONE, MANGANESE CATIONS | CELANESE CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236213-A1 | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses | COASY, HMGCR, ACACA | TP53 791/4885ALOX15 247/4885PLA2G2A 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.